Additionally, Patel and colleagues employed the JAK/STAT inhibitor, ruxolitinib, in combination with VSV-IFNβ, and they found that inhibition of JAK/STAT signaling improved VSV-IFNβ therapy for lung cancer (21). The gene discussed is SOAT1; the disease is lung carcinoma.